Evidence map›Paper›PMID 28161880›Full record

Observational studyJournal of endocrinological investigation2017

Long-term safety and efficacy of Omnitrope

D Ferone, E Profka, V Gasco, M R Ambrosio, A Colao, C Di Somma, E Puxeddu, G Arnaldi, C Pagano, E Zecchi and 2 more

Erratum issuedOpen access · hybridAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of endocrinological investigation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Observational
  2. Sir Jeffrey Hudson, the midget of the Queen Henrietta Marie.Journal of endocrinological investigation · 2018
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 2 countries.

D FeroneEndocrinology Unit, Department of Internal Medicine and Medical Specialties (DiMI), Center of Excellence for Biomedical Research (CEBR), IRCCS AOU San Martino-IST, University of Genova, Viale Benedetto XV, 6, 16132, Genova, Italy. ferone@unige.it.
E ProfkaEndocrinology and Metabolic Diseases Unit, Department of Clinical Sciences and Community Health, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca' Granda Ospedale Maggiore Policlinico, University of Milano, Milan, Italy.
V GascoEndocrinology, Diabetes and Metabolism, Department of Medical Science, Città della Salute e della Scienza di Torino, University of Torino, Turin, Italy.
M R AmbrosioSection of Endocrinology and Internal Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
A ColaoDepartment of Clinical Medicine and Surgery, University Federico II of Napoli, Naples, Italy.
C Di SommaInstitute of Diagnostic and Nuclear Research, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico SDN, Naples, Italy.
E PuxedduVeterinary and Forensic Biotechnological Sciences Department of Medicine Section, Internal Medicine, Endocrine and Metabolic Sciences, University of Perugia, Perugia, Italy.
G ArnaldiClinica di Endocrinologia e Malattie del Metabolismo, Ospedali Riuniti di Ancona, Ancona, Italy.
C PaganoDepartment of Medicine, Internal Medicine 3, University of Padova, Padua, Italy.
E ZecchiSandoz S.p.A., Origgio, VA, Italy.
A PietropoliHexal AG, Holzkirchen, Germany.
P Beck-PeccozEndocrinology and Diabetology Unit, Medical Sciences Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Cà Granda Ospedale Maggiore Policlinico, Milan, Italy.
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITHexal (Germany) · DEOspedale Policlinico San Martino · ITOspedali Riuniti di Ancona · ITSDN Istituto di Ricerca Diagnostica e Nucleare · ITUniversity of Ferrara · ITUniversity of Naples Federico II · ITUniversity of Padua · ITUniversity of Perugia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo report the long-term effectiveness and safety of the recombinant human growth hormone Omnitrope

methodsThe PATRO Adults study is an ongoing observational, longitudinal, non-interventional global post-marketing surveillance study, conducted in several European countries. The primary endpoint is long-term safety; secondary endpoints include the effectiveness of Omnitrope

resultsSixty-seven patients (mean age 50.4 years, 61.2% male) have been enrolled and have received a mean 45.4 ± 24.3 months of Omnitrope

conclusionsThis study confirms the effectiveness and safety of Omnitrope

Indexed as

AdultAgedBody HeightBone DensityFemaleGrowth DisordersHuman Growth HormoneHumansLongitudinal StudiesMaleMiddle AgedSafetyHuman Growth HormoneGrowth hormone deficiencyHypopituitarismInsulin-like growth factor-1Omnitrope®Recombinant human growth hormoneSafety

Identifiers

PMID28161880
PMCPMC5443881
OpenAlexW2585229635

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.